2 results about "Bosentan" patented technology

This invention provides a combination therapy method to increase the effectiveness of cancer immunotherapy. [Solution] The present invention provides a combination therapy using bosentan and a checkpoint inhibitor that is effective in treating cancer in a target or inhibiting the proliferation of tumor cells, and / or can induce, enhance, or prolong an immune response against tumor cells. The effectiveness of cancer immunotherapy depends on whether T cells can migrate to the tumor, travel to locations adjacent to malignant cells, recognize them, and kill them.

The present application belongs to the technical field of medicine, and particularly relates to a pharmaceutical composition and use thereof. The pharmaceutical composition composed of a PGI2 receptor agonist compound or a pharmaceutical salt thereof and bosentan has a synergistic effect on inhibiting K+ induced pulmonary artery ring tension increase and / or inhibiting PDGF induced human pulmonary artery smooth muscle cell proliferation. The combined pharmaceutical composition is more helpful for treating the disease of a patient with pulmonary arterial hypertension which cannot be controlled by a single drug. The combined pharmaceutical composition has a stronger synergistic effect on inhibiting K+ induced pulmonary artery ring tension increase and / or inhibiting PDG induced human pulmonary artery smooth muscle cell proliferation than the combined use of the existing drug selexipag and bosentan at a specific ratio and test concentration. Therefore, the combined pharmaceutical composition at a specific ratio and test concentration is more helpful for treating the disease of a patient with moderate to severe pulmonary arterial hypertension which cannot be controlled by the combined use of the existing drug selexipag and bosentan.